Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus Bio
(NQ:
CHRS
)
0.9939
-0.0061 (-0.61%)
Streaming Delayed Price
Updated: 12:33 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Coherus Bio
< Previous
1
2
3
4
5
6
7
Next >
Why Coherus BioSciences Stock Popped Today
October 05, 2023
Coherus resubmitted a license application for a key product today. Here's what investors need to know.
Via
The Motley Fool
4 Analysts Have This to Say About Coherus BioSciences
September 26, 2023
Via
Benzinga
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
September 25, 2023
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of...
Via
Benzinga
Exposures
Product Safety
Why Coherus BioSciences Stock Was Plunging This Week
September 08, 2023
The "index effect" is real, although typically not long-lasting.
Via
The Motley Fool
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
September 02, 2023
ABNB and BX will join Sept. 18 as part of a quarterly rebalancing.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Why Coherus BioSciences Stock Popped Today
August 03, 2023
The immuno-oncology leader delivered a strong second quarter.
Via
The Motley Fool
Analyst Ratings for Coherus BioSciences
August 03, 2023
Via
Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
August 03, 2023
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90...
Via
Benzinga
Earnings Preview For Coherus BioSciences
August 01, 2023
Via
Benzinga
10 Analysts Have This to Say About Coherus BioSciences
July 14, 2023
Via
Benzinga
Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
August 03, 2023
Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares jumped 75% to $9.60.
Via
Benzinga
Health Care Company Coherus BioSciences Announces Merger With Surface Oncology
June 16, 2023
Via
Benzinga
Analyst Expectations for Coherus BioSciences's Future
June 15, 2023
Via
Benzinga
Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients
June 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
July 24, 2023
Via
Benzinga
Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details
July 19, 2023
Since launching the Mark Cuban Cost Plus Drug Company in 2022, entrepreneur and NBA team owner Mark Cuban has been on a mission to lower the cost of medicines for consumers.
Via
Benzinga
Cramer Is Still Bullish On AI Company Up 155% YTD: 'I Remain A Buyer'
July 11, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he's surprised by the slow progress of Rambus Inc. (NASDAQ: RMBS).
Via
Benzinga
Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability
June 20, 2023
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc.
Via
Benzinga
Nasdaq Down 80 Points; US Consumer Sentiment Surges To 4-Month High In June
June 16, 2023
U.S. stocks traded lower toward the end of trading, with Nasdaq Compsoite dropping around 80 points on Friday. The Dow traded down 0.24% to 34,324.18 while the NASDAQ fell 0.59% to 13,701.06. The S&P...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 16, 2023
Via
Benzinga
Stocks Headed For Strong Weekly Wins
June 16, 2023
Stocks are struggling for direction midday, but all three major indexes are on track for strong weekly gains.
Via
Talk Markets
Why Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 16, 2023
Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781.
Via
Benzinga
Crude Oil Rises; Adobe Posts Upbeat Results
June 16, 2023
U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday. The Dow traded up 0.06% to 34,428.13 while the NASDAQ rose 0.05% to 13,789.23. The S&P 500,...
Via
Benzinga
Coherus BioSciences, MicroVision, Millicom And Other Big Stocks Moving Lower On Friday
June 16, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording losses in today’s session. Coherus BioSciences, Inc. (NASDAQ: CHRS) tumbled 16.8%...
Via
Benzinga
US Stocks Mixed; Dow Gains 50 Points
June 16, 2023
U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.16% to 34,464.01 while the NASDAQ fell 0.14% to...
Via
Benzinga
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
June 16, 2023
Coherus' biosimilar to Humira could catapult the company to success.
Via
The Motley Fool
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
June 16, 2023
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that
Via
Benzinga
AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry
June 15, 2023
AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.